Displaying drugs 676 - 700 of 11915 in total
Nilotinib
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant...
Approved
Investigational
Matched Description: … Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment ... found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a ... A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Acer rubrum pollen
Acer rubrum pollen is the pollen of the Acer rubrum plant. Acer rubrum pollen is mainly used in allergenic testing.
Approved
Vemurafenib
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann...
Approved
Matched Description: … Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E ... After approval, Roche in collaboration with Genentech launched a broad development program. [L1012] …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Remoxipride
Remoxipride is an atypical antipsychotic agent that is specific for dopamine D2 receptors. It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]
Approved
Withdrawn
Celiprolol
Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris. It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 receptor antagonist. In 2010 a clinical trial has suggested a use for this medication in the prevention of...
Approved
Investigational
Matched Description: … It is simultaneously a selective β1 receptor antagonist, a β2 receptor partial agonist and a weak α2 ... In 2010 a clinical trial has suggested a use for this medication in the prevention of vascular complications ... of a rare inherited disease called vascular Ehlers–Danlos syndrome. …
Famtozinameran
The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). As of November 2022, it is the primary circulating variant of...
Approved
Investigational
Matched Description: … The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. …
Vilazodone
Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622]. Vilazodone may also be associated with less sexual dysfunction and weight gain . Vilazodone was given FDA approval on January 21, 2011[L6046,A177622].
Approved
Matched Description: … Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine …
Deflazacort
Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label]
Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which...
Approved
Investigational
Matched Description: … Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular …
Treprostinil
Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease.[L41855,L41860] The first agent approved for the treatment...
Approved
Investigational
Matched Description: … Treprostinil is a stable tricyclic analogue of prostacyclin[A248770] that promotes the vasodilation of ... [L41855,L41860] The first agent approved for the treatment of PAH was [epoprostenol], a synthetic prostacyclin …
Ledipasvir
Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most...
Approved
Matched Description: … Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat ... HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 ... It is effective against genotypes 1a, 1b, 4a, and 5a and with a lesser activity against genotypes 2a …
Halazepam
Halazepam is a benzodiazepine derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United States, and was withdrawn by Schering, its manufacturer, in 2009.[L6226, L6229]
Approved
Illicit
Withdrawn
Matched Description: … Halazepam is a _benzodiazepine_ derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle …
Quinethazone
Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.
Approved
Matched Description: … Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. …
Sarecycline
Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe facial acne vulgaris [A39993,...
Approved
Investigational
Matched Description: … s Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic ... Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals ... Medical Dermatology portfolio, before Almirall acquired the portfolio in the second half of 2018 as a …
Tafamidis
Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
Approved
Investigational
Cisatracurium
Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available in its salt form, cisatracurium besylate.[A243416,A253592] Cisatracurium has an intermediate duration of action and is one of the most commonly used neuromuscular blocking agents in intensive care.[A253592,A253597]. Cisatracurium acts on cholinergic receptors, blocking neuromuscular transmission. This action is...
Approved
Investigational
Matched Description: … [A243416] Compared to atracurium, cisatracurium produces a lower degree of histamine release. ... Cisatracurium is a non-depolarising neuromuscular blocking agent of the benzylisoquinolinium class, available …
Interferon alfa-n1
Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes.
Approved
Investigational
Taliglucerase alfa
Taliglucerase alfa is the recombinant active form of the human lysosomal enzyme, β-glucocerebrosidase. It was approved in 2012 and is marketed under the name Elelyso for use in patients with type 1 Gaucher's disease.
Approved
Investigational
Omadacycline
Omadacycline has been used in trials studying the treatment of Bacterial Pneumonia, Bacterial Infections, Community-Acquired Infections, and Skin Structures and Soft Tissue Infections. Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown to be highly effective in animal models at treating increasingly problematic, clinically prevalent...
Approved
Investigational
Matched Description: … Omadacycline represents a significant advance over the well-known tetracycline family, and has been shown …
Hexocyclium
Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. It was once available under the tradename Tral marketed by Abbvie Inc. but has been discontinued. Proton pump inhibitors like DB00338 and opiate anti-diarrheal agents like DB00836 have largely replaced the...
Approved
Matched Description: … Hexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment …
Glucagon
Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.[L7634,L7637,L7640,L7643,L8519] Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.[L7640,L7643]
Glucagon was granted FDA...
Approved
Matched Description: … Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit …
Scorpion (centruroides) immune Fab2 antivenin (equine)
Centruroides (scorpion) Immune F(ab')2 (equine) is a purified preparation of immune globulin F(ab’)2 fragments that are derived from plasma of the horses immunized with venom of C. noxius, C. l. limpidus, C. l. tecomanus, and C. s. suffusus. It is intravenously administered patients with clinical signs of scorpion envenomation so...
Approved
Matched Description: … This drug is a polyvalent antivenin proven to be useful against scorpion stings. ... Centruroides (scorpion) Immune F(ab')2 (equine) is a purified preparation of immune globulin F(ab’)2 ... Envenomation by a scorpion sting can result in serious cardiovascular effects [A32483]. …
Displaying drugs 676 - 700 of 11915 in total